Parallel Advisors, LLC Tricida, Inc. Transaction History

Parallel Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$8.51 - $13.6 $1,506 - $2,407	177 Added 983.33%	195 $2,000
Q2 2022 Aug 01, 2022	BUY	$7.31 - $11.85 $131 - $213	18 New	18 $0
Q1 2022 Apr 28, 2022	SELL	$7.35 - $10.63 $271 - $393	-37 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$4.19 - $9.56 $155 - $353	37 New	37 $0
Q1 2021 Apr 23, 2021	SELL	$4.52 - $7.8 $162 - $280	-36 Closed	0 $0

Q4 2020 Feb 02, 2021	SELL	$4.37 - $9.46 $231 - $501	-53 Reduced 59.55%	36 $0
Q3 2020 Oct 27, 2020	BUY	$8.56 - $26.93 $761 - $2,396	89 New	89 $1,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.